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weighted metric. METHODS: Data were pooled from two 
identical ten-week, multicenter, randomized, double-blind,
placebo-controlled studies of ﬂexible-dose venlafaxine XR
(37.5–300mg/day; mean daily doses in the individual studies
were 132mg and 130mg) and sertraline (50–200mg/day; mean
daily doses in the individual studies were 89mg and 88mg) in
the treatment of DSM-IV MDD (1352 ITT patients). Three
health states were deﬁned using HAM-D17 scores: remission =
HAM-D £ 7; response = HAM-D between eight and 15; no
response = HAM-D > 15. The extended individual model of
Quality-Adjusted Time Without Symptoms and Toxicity (Q-
TWiST) method was applied to develop quality-adjusted remis-
sion days (QUARE), which evaluates treatment trade-offs by
incorporating the duration and patient preference (ie, utility)
associated with each health state. Effectiveness was measured by
the treatment difference on average QUARE days using an
ANOVA model with center as a covariate. Threshold utility
analysis was applied to address the utility uncertainty as a sen-
sitivity analysis. RESULTS: Over the ten-week acute treatment
period, venlafaxine XR was associated with signiﬁcantly more
QUARE days than placebo at all possible utility scenarios (P <
0.05). Sertraline was also associated with signiﬁcantly more
QUARE days than placebo at majority of possible utility sce-
narios. CONCLUSIONS: QUARE is a utility-based measure that
could be used as QALY (Quality Adjusted Life Years) directly in
cost-effectiveness studies. Different deﬁnitions of health states
can be applied to derive QUARE in MDD. Venlafaxine XR and
sertraline were associated with signiﬁcantly more QUARE days
than placebo in ten-week acute treatment of MDD.
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Depression is ranked as having the fourth greatest disease burden
worldwide measured by Disability Adjusted Life Years (DALYs).
Despite the impact of depression on overall morbidity, a signiﬁ-
cant proportion of patients go undiagnosed because the presence
of somatic and painful physical symptoms masks depression.
OBJECTIVES: The aim of this literature review is 1) to assess
existing Patient Reported Outcome (PRO) instruments validated
for use in depression; and 2) to identify to what extent they cover
the whole range of symptoms, especially those somatic and
painful physical symptoms that might hinder recognition of
depression. METHODS: A systematic literature review of pub-
lished studies was conducted using MEDLINE (1951–2004),
EMBASE (1974–2004), and the Mapi Research Trust databases.
Only studies with named, referenced PRO instruments used in
depressed patients were reviewed. The search was restricted to
idiopathic depression. RESULTS: Fifty-nine PRO instruments
were identiﬁed and of those with sufﬁcient data on psychomet-
ric properties, 22 retained for review. Of these, six covered pri-
marily emotional symptoms, three covered somatic symptoms
and 13 both. Excluding the six PRO instruments focused on
emotional symptoms, 16 instruments (eight Quality of Life, two
Activities-of-Daily-Living, four Utility, one Satisfaction and one
Work Productivity) were included in the review. Despite the
variety of PRO instruments covering a wide range of domains,
only a small number presented comprehensive psychometric val-
idation. Indeed, only ﬁve instruments were studied for their
responsiveness to clinical change. CONCLUSION: No single
instrument provides comprehensive coverage of all symptoms of
depression (including emotional, somatic and painful physical
symptoms) and a well documented psychometric validation
status. This literature review suggests the need for additional
work on the responsiveness of instruments in assessing physical
symptoms of depression, as well as further development of
patient satisfaction and work productivity questionnaires.
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OBJECTIVE: Examine the mean difference in hospitalization
and emergency room (ER) visit rates pre and post-initiation on
olanzapine, quetiapine or risperidone. METHODS: Retrospec-
tive analysis of a commercial claims database capturing inpa-
tient, outpatient and prescription drug services. Individuals
having a mental illness diagnosis, and initiated with olanzapine
(N = 8730), quetiapine (N = 5709) or risperidone (N = 9339)
between July 1, 1998 and July 2, 2002 were identiﬁed. Mean
differences in the hospitalization or ER visit rates between the
pre- and post- six month periods across the three-treatments
were examined using ANCOVA, controlling for age, gender,
region, and type of mental illness diagnosis. RESULTS: Individ-
uals initiated with olanzapine or risperidone were found to have
a signiﬁcantly higher difference in the hospitalization (2.19%, p
< 0.0001; 1.72%, p < 0.0001) or ER visit rates (3.80, p < 0.0001;
4.60%, p < 0.0001) post initiation of medication compared to
the six months prior to initiation of medication. In contrast, indi-
viduals who were initiated with quetiapine had a signiﬁcantly
lower difference in the hospitalization (-4.37%, p < 0.0001) or
ER visit rates (-2.89%, p < 0.0001) post-initiation of quetiap-
ine compared to the six months prior-initiation of quetiapine.
CONCLUSION: Quetiapine, unlike olanzapine or risperidone,
may be associated with fewer hospitalizations and ER visits 
after medication initiation. These results may be suggestive of a
more favorable side effect proﬁle and/or better compliance with
Quetiapine, and needs further investigation.
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OBJECTIVE: The severe and persistently mentally (SPMI) have
greater rates of metabolic disorders than the general population
(GP). Wellness programs have demonstrated a reduction in
health care costs for the GP. A program designed to reduce the
rate of metabolic disorders and their risk factors may prove to
signifcantly reduce annual health care cost in the SPMI. The
study goal was to evaluate the effect on metabolic syndrome 
risks of a psychoeducation program designed for SPMI.
METHOD: Overweight patients were randomly selected for 
participation in the study. A psychoeducation program 
which included modules on nutrition and active exercise was
developed and tested. The study had a acute(1hr. 3 X week)
phase for three-months and a maintenance phase (1hr. 1 X
month) for three-months. Vitals and lab tests were taken every
398 Abstracts
three-months. RESULTS: Subject Characteristics: N = 18; 
39 + 10 years (22–59); ﬁve males; 15 schizophrenics; BMI > 30.
Waist circumference—(male > 40in)-Baseline (B): 100%, Acute
(A): 60%*, Maintenance (M): 60%* (female > 35in)-(B):100%,
(A):77%*, (M): 77%*. Weight (lbs)—(B):259, (A):247,
(M):250. Cholesterol—(B):203, (A):185*, (M):186*. Triglyc-
erides—(B):151, (A):113*, (M):144. HDL—(B):41, (A):54*,
(M):47*. Glucose—(B):94, (A):85*, (M):91. Exercise compli-
ance (3 X week)—(B):11%, (A):89%*, (M):33%*. Metabolic
Syndrome—(B):50%, (A):11%*, (M):39%. *P < 0.05 (student 
t or X2). CONCLUSION: SPMI subjects had reductions in 
metabolic syndrome risks and improvement in health status
demonstrated by decrease in waist size, glucose, cholesterol and
triglycerides and an increase HDL. Some beneﬁts were lost when
subjects curtailed exercise compliance in maintenance phase. The
sample size limits our ability to make population inferences, 
yet ﬁndings suggest that a psychoeducation program including
nutrition/exercise modules should be universally available,
encouraged and ongoing to have maximum health beneﬁt and
reduction in overall health costs.
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OBJECTIVES: Numerous side effects are known to be associ-
ated with psychotropic medications. In our previous research we
have shown that side effects associated with asthma therapy
affect patient quality of life and medication adherence. The goal
of this study was to explore psychiatric patient perceptions about
side effects and to assess their interaction with quality of life
(QOL, SF-36 RAND questionnaire) and medication compliance
(Morisky scale). METHODS: A convenience sample of 19 con-
secutive patients with psychiatric disorders has been surveyed
(schizophrenia—8, schizoaffective disorder—4, bipolar disorder
—4, recurrent depressive disorder—3). All patients were using
at least one medication for their therapy. The patients were asked
to recall their use of medicines during the last two weeks. The
survey consisted of a symptom checklist (SC) that consisted of
140 side effects associated with most commonly prescribed med-
ications. The patients were asked to indicate whether they expe-
rienced each symptom listed in the checklist and whether they
felt that each symptom they had was caused by their medica-
tions. The patients were also asked to evaluate intensity of their
physical and emotional suffering due to side effects during the
last two-weeks from zero (no suffering) to ten (the most severe
suffering) and indicate the number of days they suffered from
side effects during the last two-weeks. RESULTS: Two parame-
ters of QOL were negatively associated with side effects with
borderline signiﬁcance: intensity of side effects and social func-
tioning (p = 0.06) and limiting of physical functioning and
number of days of suffering from side effects (p = 0.06). There
was no association between medication adherence and side
effects. Lower medication adherence was associated with lower
emotional functioning (p = 0.04). CONCLUSIONS: We con-
cluded that the side effects associated with psychiatric medica-
tions might affect quality of patient care. Further studies with
larger sample size are needed.
MENTAL HEALTH—Schizophrenia
PMH45
HISTORY OF SUBSTANCE ABUSE ASSOCIATED WITH POOR
PROGNOSIS IN THE TREATMENT OF SCHIZOPHRENIA:
RESULTS FROM A CLINICAL TRIAL DATABASE
Kinon B, Liu-Seifert H, Adams DH
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: This research was conducted to determine if
history of substance abuse confers poor prognosis in schizo-
phrenia as measured by onset of illness and treatment outcome.
METHODS: This was a post hoc, pooled analysis of four ran-
domized, double-blind, 24–28 week studies of schizophrenia
treatment. All treatment groups were collapsed for a total of
1627 patients and 142 patients with a history of substance abuse
at any time. Positive and Negative Syndrome (PANSS) scores and
onset of illness were compared between patients who had history
of substance abuse (males, n = 116; females, n = 26) and patients
who did not have history of substance abuse (males, n = 932;
females, n = 533) using analysis of variance. RESULTS: Patients
with a history of substance abuse had an earlier onset of illness
in both male and female patients. History of substance abuse also
had a negative effect on treatment outcomes. Speciﬁcally,
patients with a history of substance abuse had less improvement
in PANSS total and subscores than other patients. The differ-
ences in PANSS total (p < 0.01), PANSS positive (p = 0.02),
PANSS negative (p = 0.03), and PANSS general psychopathol-
ogy (p = 0.02) scores were statistically signiﬁcant for male
patients with history of substance abuse. CONCLUSIONS:
History of substance abuse is an important factor to consider
when treating patients with schizophrenia, as these patients have
an earlier onset of schizophrenia and poor response to treatment
compared to other patients. Further studies are needed to deter-
mine if substance abuse promotes schizophrenia onset; or alter-
natively, certain traits predispose individuals to both substance
abuse and schizophrenia.
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OBJECTIVES: Research on the effects of an intervention on hos-
pital length of stay and discharge are often confounded by socio-
economic factors unrelated to the intervention. The Readiness
for Discharge Questionnaire (RDQ) is a newly developed tool
designed to assess readiness for discharge of inpatients with
schizophrenia, independent of socio-economic factors. This
study examined the psychometric properties of the RDQ.
METHODS: The RDQ consists of six items assessing suicidal-
ity/homicidality, control of aggression/impulsivity, activities of
daily living, medication-taking, delusions/hallucinations interfer-
ing with functioning and global clinical status. A ﬁnal yes/no
question assesses readiness for discharge. Data from a pilot study
(n = 149) and a large randomized double-blind study (n = 382)
were used to examine test-retest reliability, construct validity,
and responsiveness. A third study (32 raters, six cases) provided
data on content validity and inter-rater reliability. RESULTS:
The inter-rater reliability was high for all items of the RDQ (reli-
ability coefﬁcient > 0.9) and moderate/high for the readiness for
discharge status (84% agreement, kappa 0.39, polychoric corre-
